FDA signals interest in regulating therapies that target aging
A news article about a 2026 aging research meeting reports that FDA officials presented possible paths for evaluating therapies aimed at aging biology, including showing slower decline in function compared with control groups.
Source: FDA Signals Interest in Regulating Therapies That Target Aging (longevity.technology). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
The article describes a presentation by FDA officials, the United States drug regulator, at a 2026 aging research meeting. According to the text, the officials presented two possible paths for evaluating therapies that aim to act on the biology of aging. One is showing that people's function declines more slowly than that of control groups. The article says these proposals illustrate how regulators could assess whether future drugs can slow aging, which would shape how such therapies are tested.
Regulators do not currently treat aging itself as a disease for drug approval purposes, and clinical trials usually measure outcomes linked to specific diseases. Measuring whether a treatment slows aging is a scientific challenge, because it requires following people over long periods and defining reliable indicators. Signals like this therefore point to an ongoing discussion rather than an approved rule. The article itself does not present study results showing benefits of any treatment.
What it means
This suggests regulators are studying how to measure whether a treatment could slow aging. No defined rule or approved drug for that purpose exists yet, and it is unclear which methods will be accepted in the future.
How to read it with care
This article does not replace a medical consultation. Anyone considering a change in diet, supplements or treatment should talk to a doctor or another qualified health professional before making any decision.